Lynparza approved in China as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer


22 September 2022 - One in two women with advanced ovarian cancer has an HRD positive tumour.

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD) positive status.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , China